Special Investment Contracts

Skopinpharm is a key participant in major SPIC projects. A SPIC is an agreement between a private investor and the Russian government, and it is aimed at long-term industrial production development in Russia.

In 2018, Skopinpharm was among the first companies to sign a SPIC. In 2021, it was the first one to sign a SPIC 2.0 - an updated version with a public tendering process that aims to establish serial innovative product production in Russia.

SPIC 1.0
Production of biopharmaceuticals and plasma products
About the project

In 2018, the Ministry of Industry and Trade, the Ryazan Oblast Administration, Octapharma-Pharmimex LLC, Pharmimex JSC, and Skopinpharm signed a SPIC to implement a large-scale investment project in Ryazan Oblast.

It envisaged using the Skopinpharm capacities (Skopin) for full cycle production of biopharmaceuticals, active ingredients, and human plasma products, including those with no equivalent produced in Russia.

+

unique biopharmaceuticals
K m2

area of the new biopharmaceutical building, including plasma fractionation areas and a laboratory complex
k liters

of plasma per year – the full-cycle plant capacity, currently being constructed under the SPIC
+

regional centers that collect plasma to supply it to Skopinpharm (to be launched in 2023-2025)
Products

As a specific drug class, plasma-derived medicinal products are often the only efficient option to manage life-threatening conditions in the case of injury, congenital disease, or immune deficiency.

Under the project, Skopinpharm transfers technologies for full-cycle production of biopharmaceuticals, like Nuwiq, Rhesonativ, Octagam 5%, Octagam 10%, Octanine, Octanate, Octaplex, Wilate, Albumin, etc.

Project value
1
To substitute import of multiple vital drugs, including those not yet produced in Russia.
2
To transfer technologies and develop production competences in a new segment for Russian pharmaceutical industry.
3
To provide the industry with local raw materials by establishing the infrastructure to collect and preserve plasma in compliance with international requirements and standards.
SPIC 2.0
Producing antitumor drugs (protein kinase inhibitors) and cancer diagnostics equipment
About the project

In 2021, the Ministry of Industry and Trade and the Ryazan Oblast Administration entered into a publicly tendered SPIC with Skopinpharm to produce antitumor drugs and cancer diagnostics equipment.

The project envisages a large-scale Skopinpharm facilities upgrade and the launch of a full cycle production of six oncology and hematology drugs, with five of them having no equivalent in Russia.


unique oncology and hematology drugs

unique technology for tumor visualization and sentinel lymph node detection
m2

area of the new Skopinpharm facilities for producing cytostatics

jobs for qualified staff
Products and technologies

SPIC 2.0 envisages transferring the technology to produce modern drugs for treating malignant melanoma, kidney, lung, pancreatic, and breast cancers, as  well as myelofibrosis, polycythemia vera, and thrombocytopenia associated with idiopathic thrombocytopenic purpura.

On top of that, the project includes producing radiopharmaceuticals for cancer diagnosis and treatment, as well as implementing a system for tumor visualization and sentinel lymph node detection.

Project value
1
To provide Russian patients with unique clinically effective antitumor drugs.
2
To create options for early detection of serious diseases and to increase therapy effectiveness.
3
To develop a pharmaceutical cluster in Ryazan Oblast that includes 10+ core enterprises and leading local educational institutions.

Are you
a healthcare professional?

Yes No